.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The REACT trial evaluated whether adding the oral phosphodiesterase-4 inhibitor roflumilast to inhaled maintenance therapy could reduce exacerbations in patients with severe COPD, chronic bronchitis, and a history of frequent exacerbations. Participants received roflumilast or placebo alongside background inhaled corticosteroid/LABA therapy, with some also receiving tiotropium. The investigators found a reduction in exacerbation frequency with roflumilast, with the clearest signal emerging in analyses that accounted for treatment adherence and protocol factors. The study also highlighted an important clinical trade-off: adverse events and treatment discontinuations were more common with roflumilast. For HCPs, the message is one of phenotype-directed escalation rather than broad use. Roflumilast is most relevant when chronic bronchitis, severe airflow limitation, and recurrent exacerbations persist despite optimized inhaled therapy. Tolerability and patient selection matter because gastrointestinal and other adverse effects can limit long-term use. This evidence fits the conference focus on COPD beyond spirometry, where exacerbation pattern, symptom phenotype, exposure history, and treatment response help guide more individualized management.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The REACT trial evaluated whether adding the oral phosphodiesterase-4 inhibitor roflumilast to inhaled maintenance therapy could reduce exacerbations in patients with severe COPD, chronic bronchitis, and a history of frequent exacerbations. Participants received roflumilast or placebo alongside background inhaled corticosteroid/LABA therapy, with some also receiving tiotropium. The investigators found a reduction in exacerbation frequency with roflumilast, with the clearest signal emerging in analyses that accounted for treatment adherence and protocol factors. The study also highlighted an important clinical trade-off: adverse events and treatment discontinuations were more common with roflumilast. For HCPs, the message is one of phenotype-directed escalation rather than broad use. Roflumilast is most relevant when chronic bronchitis, severe airflow limitation, and recurrent exacerbations persist despite optimized inhaled therapy. Tolerability and patient selection matter because gastrointestinal and other adverse effects can limit long-term use. This evidence fits the conference focus on COPD beyond spirometry, where exacerbation pattern, symptom phenotype, exposure history, and treatment response help guide more individualized management.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
5 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
